Registration Now Open for NPE2024: The Plastics Show
The Plastics Industry Association (PLASTICS) announced today that NPE2024: The Plastics Show registrations are now open through May 2024. NPE2024 will be the most impactful trade show of the year for all plastics industry sectors in the U.S. and globally, with more than 55,000 attendees expected.
Every three years, NPE offers the plastics industry a global platform to highlight innovation across a show floor with more than 1.1 million net square feet of exhibit space at the Orange County Convention Center in Orlando, Fla. Matt Seaholm, President and CEO of PLASTICS, highlighted that NPE2024 will return bigger and better than ever, “We look forward to welcoming our industry back to NPE2024: The Plastics Show next May. The plastic industry serves a critical and sustainable role in modern life; this show will be a testament to that.”
“With sustainability at the center of everything produced at the show, attendees will witness new technologies and significant education opportunities to push us toward a more circular economy and help our industry continue to grow,” said Seaholm.
NPE2024 returns, with the theme Made for You, where attendees are front and center of all experiences happening at the show. The event, held May 6-10, 2024, will offer opportunities for everyone in the industry, even those just starting their career. Some notable experiences at NPE2024 include:
- Six technology zones with 2,000+ exhibitors showcasing their latest products and services
- More than 100 speaker presentations on trending topics that foster innovation, drive circularity and exemplify collaboration
- The brand-new NPE Circularity Hub where attendees will experience the plastics circular economy, from raw materials to go-to market consumer products
- Influential women in the plastics industry will share their success stories with those attending the Women in Plastics Breakfast
- More than 355 first-time exhibitors bringing to NPE2024 new products and perspectives
- The inaugural NPE Opening Night Party featuring the band Pop Rocks, games, food and drinks
NPE2024 attendees will gain exclusive access to the entire plastics supply chain, including machinery and equipment, raw materials, recycling and sustainability, automation and robotics, 3D and 4D printing, inspection, design, and more. NPE exhibitors service vital markets such as automotive, consumer products, recycling, packaging, medical, and building and construction.
Important dates to remember if planning on attending NPE2024:
- Attendee registration for NPE2024 opens on Tuesday, September 12, 2023
- Registration for the hotel room block also begins on Tuesday, September 12, 2023
- NPE2024 event dates are May 6-10, 2024, at the Orange County Convention Center in Orlando, Fla.
Tickets for NPE2024 range from $100 - $600; prices vary depending on early bird, advanced and on-site sales. Add-ons to the NPE Opening Night Party, Women in Plastics Breakfast, Seminarios Latinoamericanos, and 3D Printing for Plastic Processors are also available on a first-come, first-served basis, inquire for details.
“NPE2024 is at the forefront of the plastics future. If you want to further your career, grow your company or keep up with new trends and solutions, NPE2024 is where you need to be in May 2024. We encourage you to register today and start planning and customizing your experience as we continue to reveal all the exciting things happening at the event,” concluded Steve London, NPE2024 Committee Chair.
For more information about NPE2024: The Plastics Show and to register, visit: NPE.org.
The Plastics Industry Association (PLASTICS) is the only organization that supports the entire plastics supply chain, including Equipment Suppliers, Material Suppliers, Processors, and Recyclers, representing over one million workers in our $548 billion U.S. industry. PLASTICS advances the priorities of our members who are dedicated to investing in technologies that improve capabilities and advances in recycling and sustainability and providing essential products that allow for the protection and safety of our lives. Since 1937, PLASTICS has been working to make its members, and the seventh largest U.S. manufacturing industry, more globally competitive while supporting circularity through educational initiatives, industry-leading insights and events, convening opportunities and policy advocacy, including the largest plastics trade show in the Americas, NPE2024: The Plastics Show.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911029303/en/
Contact information
Elizabeth Domenech pr@npe.org
Camille Gallo cgallo@plasticsindustry.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
